                         SEQUENCE LISTING

<110>  Merck Sharp & Dohme Corp.
       Bianchi, Elisabetta
       Carrington, Paul E
       Deng, Qiaolin
       Nargund, Ravi
       Orvieto, Federica
       Palani, Anandan
       Pessi, Antonello
       Tucjer, Thomas J
       Wu, Chengwei
 
<120>  CO-AGONISTS OF THE GLUCAGON AND GLP-1 RECEPTORS

<130>  23848

<150>  62/068,157
<151>  2014-10-24

<150>  62/208,869
<151>  2015-08-24

<160>  35    

<170>  PatentIn version 3.5

<210>  1
<211>  29
<212>  PRT
<213>  Homo sapiens

<400>  1

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr 
            20                  25                  


<210>  2
<211>  30
<212>  PRT
<213>  Homo sapiens

<400>  2

His Ala Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly 
1               5                   10                  15      


Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Gly Arg 
            20                  25                  30  


<210>  3
<211>  37
<212>  PRT
<213>  Homo sapiens

<400>  3

His Ser Gln Gly Thr Phe Thr Ser Asp Tyr Ser Lys Tyr Leu Asp Ser 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Met Asn Thr Lys Arg Asn 
            20                  25                  30          


Arg Asn Asn Ile Ala 
        35          


<210>  4
<211>  39
<212>  PRT
<213>  Heloderma suspectum

<400>  4

His Gly Glu Gly Thr Phe Thr Ser Asp Leu Ser Lys Gln Met Glu Glu 
1               5                   10                  15      


Glu Ala Val Arg Leu Phe Ile Glu Trp Leu Lys Asn Gly Gly Pro Ser 
            20                  25                  30          


Ser Gly Ala Pro Pro Pro Ser 
        35                  


<210>  5
<211>  33
<212>  PRT
<213>  Homo sapiens

<400>  5

His Ala Asp Gly Ser Phe Ser Asp Glu Met Asn Thr Ile Leu Asp Asn 
1               5                   10                  15      


Leu Ala Ala Arg Asp Phe Ile Asn Trp Leu Ile Gln Thr Lys Ile Thr 
            20                  25                  30          


Asp 
    


<210>  6
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist Peptide 1


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via a gamme-Glu  spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  6

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  7
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 2


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via a gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  7

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Val 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  8
<211>  29
<212>  PRT
<213>  artificial sequence

<220>
<223>  Co-agonist peptide 3


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via a gamma-Glue gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  8

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Val 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  9
<211>  29
<212>  PRT
<213>  Artificial Sequence

<220>
<223>  Co-agonist peptide 4


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = alpha-aminoisobutyric acid (Aib)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  misc_feature
<222>  (16)..(16)
<223>  Xaa can be any naturally occurring amino acid

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa = noreleucine

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  9

His Xaa Val Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr 
            20                  25                  


<210>  10
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 5


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  10

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  11
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 6


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  11

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  12
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 7


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal acetyl group

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  12

His Ala Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  13
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 8


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  13

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  14
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 9


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = p-fluoro phenylalanine (pFF)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  14

His Xaa Gln Gly Thr Xaa Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  15
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 10


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa = methionine sulfone

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  15

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr 
            20                  25                  


<210>  16
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 11


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  16

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Leu Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  17
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 12


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa = para-aminomethyl phenylalanine (pAF) conjugated to C16 via 
       gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  17

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  18
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 13


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = 1-amino-1-cyclobutane carboxylate

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  18

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  19
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 14


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = threo-beta-phenylalanine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glue spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amide

<400>  19

His Xaa Gln Gly Thr Xaa Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  20
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 15


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  Optional N-terminal acetyl group

<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine, L-Alanine, aib, or 1-amino-cyclobutane carboylix 
       acid

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = L-Phenylalanine, p-fluoro phenylalanine, or 
       threo-beta-phenylalanine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu spacer or Lysine 
       conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa = Lysine conjugated to C16 via gamma-Glu spacer, Lysine 
       conjugated to C16 via gamma-Glu gamma-Glu spacer, or pAF 
       conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (12)..(12)
<223>  Xaa = L-Lysine or L-Leucine

<220>
<221>  MISC_FEATURE
<222>  (15)..(15)
<223>  Xaa = L-Glutamic acid, L-Leucine, or L-Aspartic acid

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa =aib, L-Alanine, L-Glutamic acid, or L-Valine

<220>
<221>  MISC_FEATURE
<222>  (18)..(18)
<223>  Xaa = L-Alanine or L-Arginine

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa = L-Leucine, methionine sulfone, or L-norleucine (Nle)

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  20

His Xaa Gln Gly Thr Xaa Thr Ser Asp Xaa Ser Xaa Tyr Leu Xaa Xaa 
1               5                   10                  15      


Arg Xaa Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr 
            20                  25                  


<210>  21
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Comparative peptide


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  C-terminal amidation

<400>  21

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  22
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  C0-agonist peptide 16


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  22

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  23
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 17


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  23

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Val 
1               5                   10                  15      


Arg Arg Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  24
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 18


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  24

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Val 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  25
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 19


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = alpha-aminoisobutyric acid (aib)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (16)..(16)
<223>  Xaa = alpha-aminoisobutyric acid (aib)

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa = L-norleucine (Nle)

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  25

His Xaa Val Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Xaa 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr 
            20                  25                  


<210>  26
<211>  29
<212>  PRT
<213>  artificial

<220>
<223>  Co-agonist peptide 20


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  26

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  27
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 21


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  27

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  28
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 22


<220>
<221>  MISC_FEATURE
<222>  (1)..(1)
<223>  N-terminal acetyl group

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  28

His Ala Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  29
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 23


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optioanl C-terminal amide or ester

<400>  29

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Glu Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  30
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 24


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = p-fluoro phenylalanine (pFF)

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  30

His Xaa Gln Gly Thr Xaa Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  31
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 25


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma--Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (27)..(27)
<223>  Xaa = methionine sulfone

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  31

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Xaa Asp Thr 
            20                  25                  


<210>  32
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 26


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  32

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Leu Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  33
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  C0oagonist peptide 27


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Xaa = para-aminomethyl phenylalanine 9pAF) conjugaed to C16 via 
       gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  33

His Xaa Gln Gly Thr Phe Thr Ser Asp Xaa Ser Lys Tyr Leu Asp Ala 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  34
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 28


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = 1-amino-1-cyclobutane carboxylic acid

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  34

His Xaa Gln Gly Thr Phe Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


<210>  35
<211>  29
<212>  PRT
<213>  Artificial sequence

<220>
<223>  Co-agonist peptide 29


<220>
<221>  MISC_FEATURE
<222>  (2)..(2)
<223>  Xaa = D-Serine

<220>
<221>  MISC_FEATURE
<222>  (6)..(6)
<223>  Xaa = threo-beta-phenylserine

<220>
<221>  MISC_FEATURE
<222>  (10)..(10)
<223>  Lysine conjugated to C16 via gamma-Glu gamma-Glu spacer

<220>
<221>  MISC_FEATURE
<222>  (29)..(29)
<223>  Optional C-terminal amide or ester

<400>  35

His Xaa Gln Gly Thr Xaa Thr Ser Asp Lys Ser Lys Tyr Leu Asp Glu 
1               5                   10                  15      


Arg Ala Ala Gln Asp Phe Val Gln Trp Leu Leu Asp Thr 
            20                  25                  


